Identification and Validation of Novel Antigenic Targets in Trypanosoma cruzi
克氏锥虫新抗原靶标的鉴定和验证
基本信息
- 批准号:7858084
- 负责人:
- 金额:$ 14.83万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-06-01 至 2011-05-31
- 项目状态:已结题
- 来源:
- 关键词:1-ButanolAdjuvantAffinity ChromatographyAlgorithmsAmericanAntibodiesAntigensBiotinylationBloodCD8B1 geneCardiomyopathiesCell membraneCell surfaceChagas DiseaseChronic PhaseClinicalCommunicable DiseasesComputational BiologyConfocal MicroscopyCountryDetergentsDevelopmentDiseaseDrug resistanceEmerging Communicable DiseasesFlow CytometryGPI Membrane AnchorsGlycoproteinsGoalsHeart failureHistocompatibilityHumanImmune responseImmunizationImmunodominant AntigensImmunotherapeutic agentImmunotherapyIndividualInfectionLabelLatin AmericaLifeLiquid ChromatographyLyticMammalsMastigophoraMembrane ProteinsMusNomadsOrganOrganic solvent productParasitesPeptidesPharmaceutical PreparationsPhylogenetic AnalysisPopulationPrevention approachProbabilityProteinsProteomicsReagentRecombinantsReportingRiskStagingStreptavidinSurfaceT-LymphocyteTexasTriton X-114Trypanosoma cruziUniversitiesVaccinationVaccinesValidationaluminum sulfatec-myc Genesimmunogenicnovelpreventprogramsprotein aminoacid sequencetandem mass spectrometryvaccine candidate
项目摘要
Chagas' disease is one of the most deadly infectious diseases in the American continent, and is caused
by the protozoan parasite Trypanosoma cruzi. Over 11 million people are infected, and about 120 million
individuals are at risk of acquiring the disease. Up to 100,000 migrants from endemic countries living in the
U.S. are thought to be infected with T. cruzi, and represent a latent risk for recipients of blood components,
and organs. Currently, only one partially effective drug is available for the treatment of Chagas' disease.
There is no human vaccine against T. cruzi.
The overall goal of this proposal is to identify and validate major immunodominant antigens that are
ubiquitously expressed on the cell surface of mammal-dwelling stages of T. cruzi for the development of new
immunotherapeutic approaches to prevent or treat Chagas' disease. To achieve this, the following specific
aims are proposed:
Specific aim # 1. Expression proteomics of the plasma membrane of trypomastigote and intracellular
amastigote forms of T. cruzi. Our primary goal is to identify by proteomic analysis the major proteins and
glycoproteins expressed on the cell surface of the mammal-dwelling stages in different phylogenetic lineages
and strains of T. cruzi.
Specific aim # 2. Functional proteomics of the cell surface of trypomastigote and intracellular
amastigote forms of T. cruzi to identify and validate novel antigenic targets for vaccination. We will perform
an extensive immunological analysis of selected surface (glyco)proteins found in specific aim # 1, to validate
them as antigenic targets for experimental vaccination. We will identify proteins that are able to induce
efficient humoral and celullar immune responses in mice. Finally, we will perform experimental immunization
with the two best antigenic targets, followed by challenge with T. cruzi to evaluate the protection against the
parasite.
Overall significance: We believe that this project will result in the identification of immunodominant
antigenic targets on the cell surface of mammal-dwelling stages of T. cruzi and in the development of new
immunotherapeutic approaches for prevention and treatment of Chagas' disease.
恰加斯病是美洲大陆最致命的传染病之一,由
被原生动物寄生虫锥虫克氏锥虫。超过1100万人感染,约1.2亿人感染
个人有感染这种疾病的风险。多达10万名来自流行国家的移民居住在
美国被认为感染了克鲁兹旋毛虫,对血液成分接受者来说是一个潜在的风险,
和器官。目前,只有一种部分有效的药物可用于治疗恰加斯病。
目前还没有针对克氏锥虫的人类疫苗。
这项提案的总体目标是识别和验证主要的免疫优势抗原,这些抗原是
在哺乳动物栖息阶段的细胞表面广泛表达,为新的发育提供依据
预防或治疗恰加斯病的免疫治疗方法。要实现这一点,需要采取以下具体措施
建议的目标是:
特定目的#1.类鞭毛虫和胞内质膜的表达蛋白质组学
克氏毛滴虫的无鞭毛体。我们的主要目标是通过蛋白质组学分析确定主要的蛋白质和
不同系统发育谱系哺乳动物栖息期细胞表面糖蛋白的表达
和克氏锥虫的菌株。
特定目标#2.类鞭毛虫细胞表面和细胞内的功能蛋白质组学
克鲁兹毛滴虫的无鞭毛体形式,以识别和验证疫苗接种的新抗原靶点。我们将表演
对在特定目标1中发现的选定表面(糖蛋白)蛋白进行广泛的免疫学分析,以验证
作为实验性疫苗接种的抗原靶点。我们将鉴定出能够诱导
小鼠有效的体液和细胞免疫反应。最后,我们将进行实验性免疫
用两个最好的抗原靶,然后用克氏锥虫进行挑战,以评估对
寄生虫。
总体意义:我们相信这个项目将导致免疫优势的识别
克鲁兹毛滴虫哺乳动物栖息期细胞表面抗原靶标及其新的发育
预防和治疗恰加斯病的免疫治疗方法
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
IGOR C ALMEIDA其他文献
IGOR C ALMEIDA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('IGOR C ALMEIDA', 18)}}的其他基金
New chemotherapy regimens and biomarkers for Chagas disease
恰加斯病的新化疗方案和生物标志物
- 批准号:
10219078 - 财政年份:2018
- 资助金额:
$ 14.83万 - 项目类别:
New chemotherapy regimens and biomarkers for Chagas disease
恰加斯病的新化疗方案和生物标志物
- 批准号:
9764253 - 财政年份:2018
- 资助金额:
$ 14.83万 - 项目类别:
New chemotherapy regimens and biomarkers for Chagas disease
恰加斯病的新化疗方案和生物标志物
- 批准号:
10469327 - 财政年份:2018
- 资助金额:
$ 14.83万 - 项目类别:
New chemotherapy regimens and biomarkers for Chagas disease
恰加斯病的新化疗方案和生物标志物
- 批准号:
9484015 - 财政年份:2018
- 资助金额:
$ 14.83万 - 项目类别:
New chemotherapy regimens and biomarkers for Chagas disease
恰加斯病的新化疗方案和生物标志物
- 批准号:
9980275 - 财政年份:2018
- 资助金额:
$ 14.83万 - 项目类别:
New chemotherapy regimens and biomarkers for Chagas disease
恰加斯病的新化疗方案和生物标志物
- 批准号:
10557245 - 财政年份:2017
- 资助金额:
$ 14.83万 - 项目类别:
Molecular Composition and Function of Trypanosoma cruzi Shed Vesicles
克氏锥虫脱落囊泡的分子组成和功能
- 批准号:
8147543 - 财政年份:2010
- 资助金额:
$ 14.83万 - 项目类别:
BIOMOLECULE CHARACTERIZATION AND SEPARATION CORE FACILITY
生物分子表征和分离核心设施
- 批准号:
7959146 - 财政年份:2009
- 资助金额:
$ 14.83万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 14.83万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 14.83万 - 项目类别:
Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 14.83万 - 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 14.83万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 14.83万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 14.83万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 14.83万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 14.83万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 14.83万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 14.83万 - 项目类别:














{{item.name}}会员




